All Stories

  1. An analysis of Relative Telomere Length (RTL) during chemotherapy in patients with advanced gastro-oesophageal adenocarcinoma v1
  2. An analysis of Relative Telomere Length (RTL) during peri-operative chemotherapy in patients with operable gastric or gastro-oesophageal junction adenocarcinoma v1
  3. A Novel Pyrazolopyrimidine Ligand of Human PGK1 and Stress Sensor DJ1 Modulates the Shelterin Complex and Telomere Length Regulation
  4. A ‘synthetic-sickness’ screen for senescence re-engagement targets in mutant cancer backgrounds
  5. Extensive telomere erosion is consistent with localised clonal expansions in Barrett’s metaplasia
  6. A multi-targeted approach to suppress tumor-promoting inflammation
  7. Broad targeting of angiogenesis for cancer prevention and therapy
  8. Broad targeting of resistance to apoptosis in cancer
  9. Cancer prevention and therapy through the modulation of the tumor microenvironment
  10. Designing a broad-spectrum integrative approach for cancer prevention and treatment
  11. Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds
  12. Genomic instability in human cancer: Molecular insights and opportunities for therapeutic attack and prevention through diet and nutrition
  13. Immune evasion in cancer: Mechanistic basis and therapeutic strategies
  14. Sustained proliferation in cancer: Mechanisms and novel therapeutic targets
  15. Therapeutic targeting of replicative immortality
  16. Tissue invasion and metastasis: Molecular, biological and clinical perspectives
  17. Identification of a Selective G1-Phase Benzimidazolone Inhibitor by a Senescence-Targeted Virtual Screen Using Artificial Neural Networks
  18. Cell-based screen for altered nuclear phenotypes reveals senescence progression in polyploid cells after Aurora kinase B inhibition
  19. Plasma N-acetyl-glucosaminidase in advanced gastro-intestinal adenocarcinoma correlates with age, stage and outcome
  20. Immortalization of T-Cells Is Accompanied by Gradual Changes in CpG Methylation Resulting in a Profile Resembling a Subset of T-Cell Leukemias
  21. Isolation, Culture, and Transfection of Melanocytes
  22. Mathematical Model of a Telomerase Transcriptional Regulatory Network Developed by Cell-Based Screening: Analysis of Inhibitor Effects and Telomerase Expression Mechanisms
  23. A Small Molecule Modulator of Prion Protein Increases Human Mesenchymal Stem Cell Lifespan, Ex Vivo Expansion, and Engraftment to Bone Marrow in NOD/SCID Mice
  24. Telomere maintenance mechanisms in malignant peripheral nerve sheath tumors: expression and prognostic relevance
  25. Cancer cell senescence: a new frontier in drug development
  26. Mesenchymal Stem Cells as Therapeutic Delivery Vehicles Targeting Tumor Stroma
  27. Response to ‘Validating a gene expression signature proposed to differentiate liposarcomas that use different telomere maintenance mechanisms’
  28. Progeroid syndromes: models for stem cell aging?
  29. Malignancy without immortality? Cellular immortalization as a possible late event in melanoma progression
  30. Targeting the telomere and shelterin complex for cancer therapy: current views and future perspectives
  31. TCEAL7 Inhibition of c-Myc Activity in Alternative Lengthening of Telomeres Regulates hTERT Expression
  32. Telomerase upregulation is a postcrisis event during senescence bypass and immortalization of two Nijmegen breakage syndrome T cell cultures
  33. Scoring of senescence signalling in multiple human tumour gene expression datasets, identification of a correlation between senescence score and drug toxicity in the NCI60 panel and a pro-inflammatory signature correlating with survival advantage in pe...
  34. Modulation of Gene Expression Using Zinc Finger-Based Artificial Transcription Factors
  35. Mining Cellular Senescence for Drug Targets
  36. A gene expression signature classifying telomerase and ALT immortalization reveals an hTERT regulatory network and suggests a mesenchymal stem cell origin for ALT
  37. The PTEN regulator DJ-1 is associated with hTERT expression in clear cell renal cell carcinoma
  38. Dynamic Telomerase Gene Suppression via Network Effects of GSK3 Inhibition
  39. Pathway analysis of senescence-associated miRNA targets reveals common processes to different senescence induction mechanisms
  40. A systems biology approach to Down syndrome: Identification of Notch/Wnt dysregulation in a model of stem cells aging
  41. A role for NANOG in G1 to S transition in human embryonic stem cells through direct binding of CDK6 and CDC25A
  42. Silencing of the expression of pluripotent driven-reporter genes stably transfected into human pluripotent cells
  43. High level of telomerase RNA gene expression is associated with chromatin modification, the ALT phenotype and poor prognosis in liposarcoma
  44. Downregulation of Multiple Stress Defense Mechanisms During Differentiation of Human Embryonic Stem Cells
  45. Targeting telomerase for cancer therapeutics
  46. Targeting Telomerase: Therapeutic Options for Cancer Treatment
  47. Telomerase redefined: Integrated regulation of hTR and hTERT for telomere maintenance and telomerase activity
  48. Stem cell ageing: does it happen and can we intervene?
  49. Seeding drug discovery: integrating telomerase cancer biology and cellular senescence to uncover new therapeutic opportunities in targeting cancer stem cells
  50. Ectopically hTERT expressing adult human mesenchymal stem cells are less radiosensitive than their telomerase negative counterpart
  51. Epigenetic control of cellular senescence in disease: opportunities for therapeutic intervention
  52. Modulation of Telomerase Promoter Tumor Selectivity in the Context of Oncolytic Adenoviruses
  53. Cancer stem cells: Opportunities for novel diagnostics and drug discovery
  54. Therapeutic potential of adult stem cells
  55. Transcriptional Repression of Telomerase RNA Gene Expression by c-Jun-NH2-Kinase and Sp1/Sp3
  56. Telomerase promoter reprogramming and interaction with general transcription factors in the human mesenchymal stem cell
  57. Properties of a Telomerase-Specific Cre/Lox Switch for Transcriptionally Targeted Cancer Gene Therapy
  58. Hypoxic regulation of telomerase gene expression by transcriptional and post-transcriptional mechanisms
  59. Synthetic Anticancer Gene Medicine Exploits Intrinsic Antitumor Activity of Cationic Vector to Cure Established Tumors
  60. Lack of Telomerase Gene Expression in Alternative Lengthening of Telomere Cells Is Associated with Chromatin Remodeling of thehTRandhTERTGene Promoters
  61. Predictive value of thymidylate synthase and dihydropyrimidine dehydrogenase protein expression on survival in adjuvantly treated stage III colon cancer patients
  62. The hTERT and hTERC Telomerase Gene Promoters Are Activated by the Second Exon of the Adenoviral Protein, E1 A, Identifying the Transcriptional Corepressor CtBP as a Potential Rearessor of Both Genes
  63. Markers of Adenocarcinoma Characteristic of the Site of Origin: Development of a Diagnostic Algorithm
  64. Application of Targeted Radiotherapy/Gene Therapy to Bladder Cancer Cell Lines
  65. Dysregulated expression of the major telomerase components in leukaemic stem cells
  66. MDM2 negatively regulates the human telomerase RNA gene promoter
  67. Drug Insight: cancer cell immortality—telomerase as a target for novel cancer gene therapies
  68. Combining a targeted radiotherapy and gene therapy approach for adenocarcinoma of prostate
  69. An efficient targeted radiotherapy/gene therapy strategy utilising human telomerase promoters and radioastatine and harnessing radiation-mediated bystander effects
  70. A mutation in a functional Sp1 binding site of the telomerase RNA gene (hTERC) promoter in a patient with Paroxysmal Nocturnal Haemoglobinuria
  71. Gastrokine 1 is abundantly and specifically expressed in superficial gastric epithelium, down-regulated in gastric carcinoma, and shows high evolutionary conservation
  72. From stem cells to cancer: balancing immortality and neoplasia
  73. Profiling, comparison and validation of gene expression in gastric carcinoma and normal stomach
  74. Selective ablation of human cancer cells by telomerase-specific adenoviral suicide gene therapy vectors expressing bacterial nitroreductase
  75. Involvement of NF-Y and Sp1 binding sequences in basal transcription of the human telomerase RNA gene
  76. Why a Special Issue on Gene Therapy?
  77. Telomerase-directed molecular therapeutics
  78. ?Senescence-associated? ?-galactosidase activity in the upper gastrointestinal tract
  79. Somatic cell hybrids
  80. Genetic Analysis of Drug Resistance by Fluorescence In Situ Hybridization
  81. Genetic Analysis of Drug Resistance by Reverse In Situ Hybridization
  82. Detection of Telomerase Enzyme Activity by TRAP Assay
  83. Detection of Telomerase hTERT Gene Expression and Its Splice Variants by RT-PCR